Cancer Vaccines Market Size, Share, Industry, Forecast and outlook (2024-2031)

Cancer Vaccines Market is segmented By Technology (Dendritic Cells Vaccines, Anti-idiotype Vaccines, Antigen Vaccines, Whole Tumor Vaccines, DNA Vaccines), By Type (Preventive Cancer Vaccines, Treatment Cancer Vaccines), By Disease Type (Cervical Cancer, Prostate Cancer, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031.

Cancer Vaccines Market Size

Cancer vaccines market size was valued USD million in 2023 and is estimated to reach USD million by 2031, growing at a CAGR of 18% during the forecast period (2024-2031). Cancer is a malignant tumor caused by uncontrollable cell development in the body.

It can be treated with a variety of drugs and vaccinations. Vaccines are widely classified as either preventative or therapeutic. Preventive cancer vaccinations are used to prevent oncovirus-caused cancer and to protect against human papillomavirus (HPV), whereas therapeutic vaccines stimulate the individual adaptive immune systems by employing tumor antigens. Cancer vaccines are available in various forms, including antigen, dendritic cell, and anti-idiotype. There are several vaccines such as personalized cancer vaccines, anthrax vaccines, and other types of vaccines.

Cancer Vaccines Market Summary

For More Insights Request Free Sample

Cancer Vaccines Market Dynamics

The Cancer vaccines market study analysis offers an in-depth outlook on the market containing both quantitative, and qualitative data. It gives an outlook and forecast of the global Cancer vaccines market based on the market segmentation by technology type, and disease type. It also provides Cancer vaccines market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global Cancer vaccines market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Increasing clinical trials for cancer vaccines by the market players is expected to drive market growth.

Pancreatic Ductal Adenocarcinoma, also known as PDAC, is a prevalent type of pancreatic cancer for which there are no effective treatments. BioNTech, a manufacturer of mRNA vaccines, released phase-1 clinical trial data for its vaccine against PDAC. The neoantigen genetic code is delivered to the patient's cells using the mRNA vaccination created by BioNTech. The neoantigens, proteins made by cancer cells, are instructed to be produced by the cells by the code. The production of these proteins aids in triggering the immune system's attack on the tumor itself. Moreover, BLENREP (belantamab mafodotin), an ADC targeting B-cell maturation antigen type used to treat multiple myeloma, is being developed by GSK plc. It is now in Phase III.

Additionally, the Oxford-AstraZeneca COVID-19 vaccine's technology also has the potential to treat cancer, according to research from the University of Oxford and the Ludwig Institute for Cancer Research. The cancer vaccination improved the effectiveness of cancer immunotherapy when evaluated in animal tumor models, where it increased the levels of anti-tumour T cells invading the tumors. The combination of immunotherapy and the vaccine demonstrated a larger tumor size decrease than immunotherapy alone, and the mice's survival improved. Furthermore, codagenix received FDA clearance for an investigational new drug application for Live-Attenuated, Intranasal RSV Vaccine Candidate CodaVax-RSV. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

The high cost of developing cancer vaccines, the longer time required for manufacturing a single vaccine and lengthy regulatory approvals are some factors the market is expected to get hampered in the forecast period.

Cancer Vaccines Market Industry Analysis

The cancer vaccines market provides in-depth analysis of the market based on various industry factors such as porter five forces, unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted the market. As the number of COVID-19 cases increased, healthcare systems worldwide focused on controlling the illness and delaying the prevention, detection, and treatment of other chronic illnesses, including cancer. Researchers at the University of Oxford and AstraZeneca Plc are attempting to create a therapeutic cancer vaccine using the same technique, with encouraging findings reported in animal experiments. After the pandemic, scientists and governments worked harder and faster than ever to produce vaccines to help contain the virus. As a result, vaccine research has evolved. Because of the crisis, technologies like messenger RNA have proven their efficacy and potential to treat other diseases like cancer. The advancements come as researchers examine other cutting-edge cancer treatments that use the immune system to fight tumors.

In contrast, the pandemic interrupts the cancer vaccine supply chain and process. Thus, the COVID-19 pandemic has affected the market. However, the situation is expected to improve gradually in the forecast period.

Cancer Vaccines Market Segmentation Analysis

Recombinant Cancer Vaccines segment is expected to hold the largest market share in the cancer vaccine market.

The recombinant cancer vaccines segment is expected to dominate in 2021. Recombinant vaccines are created using recombinant DNA technology. This involves the expression of an antigen in mammalian cells, which triggers an immunological response and purifies the antigen from these cells. Various viruses have undergone genetic modification to express tumor-associated antigens (TAA) for intramuscular or subcutaneous injection. Broad cell tropism, strong immunogenicity, and pre-existing neutralizing immunity, exclusively in those patients who received the vaccinia virus, are only a few advantageous characteristics of poxviruses as vectors for cancer vaccines (the smallpox vaccine). Canarypox, fowlpox, and vaccines have all been studied therapeutically for cancer vaccination.

Additionally, a great deal of research is being done on viral recombinant cancer vaccines, primarily for cancer vaccination, which may have favorable outcomes in the future. Therefore, it has increased the demand for recombinant cancer vaccines. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period. ​

Cancer Vaccines Market Geographical Share

North American region holds the largest market share of the global cancer vaccines market.

In 2021, North America accounted for the highest revenue share. The increasing prevalence of cancer, rising research investments, increasing clinical trials by the market players and regulatory approvals for cancer vaccines are the factors the market is driven by in the forecast period. For instance, according to the American Cancer Society, in 2021, an estimated 1.9 million new cancer cases will be diagnosed, and there will be 608,570 cancer deaths in the United States. In contrast, in 2022, roughly 1.9 million people will be diagnosed with cancer in the United States. An estimated 287,850 women and 2,710 men will be diagnosed with breast cancer, which makes it the most common cancer diagnosis. Prostate cancer is the leading cancer diagnosis among men and the second most common overall, with 268,490 expected cases. Lung and bronchus cancer is the third most common cancer diagnosis, with an estimated 236,740 new cases.

Moreover, the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting was held from May 29–31, 2020. Gilead Sciences, Inc. and Kite, a Gilead Company, announced that nine abstracts from their immuno-oncology research and development program, including three oral presentations, have been accepted. Abstracts at ASCO will showcase Kite's industry-leading cell therapy portfolio and magrolimab, an experimental anti-CD47 monoclonal antibody created by Forty-Seven, Inc., which Gilead just purchased. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Cancer Vaccines Companies and Competitive Landscape

Major key players in the cancer vaccines market are ose-immuno, Merck & Co. Inc., IO Biotech, Medigene AG, Northwest Biotherapeutics, GlaxoSmithKline, Dendreon Pharmaceuticals LLC., Dynavax Technologies Corporation, Immunophotonics, Codagenix.

Northwest Biotherapeutics Inc.:

Overview:

Northwest Biotherapeutics Inc. is a biotechnology company involved in developing cancer vaccines. The target is a broad range of solid-tumor cancers. A customized vaccination is created by the corporation using a patented manufacturing method. The product portfolio includes product candidates such as DCVax-L for patients with brain cancer, DCVax-Direct for direct injection into all forms of solid tumor malignancies that are incurable, and DCVax for late-stage ovarian cancer. The U.S. Food and Drug Administration have given approval for DCVax-Prostate, which is used to treat late-stage prostate cancer.

­Product Portfolio:

DCVAX TECHNOLOGY: DCVax is a platform technology for delivering dendritic cell based therapeutic vaccines for various cancers, including glioblastoma multiforme (GBM).